[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N: [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study]. Acta Otorrinolaringol Esp; 2003 Dec;54(10):697-703
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
  • [Transliterated title] Quimioterapia de inducción con vinorelbine, cisplatino y UFT en carcinomas avanzados faringo-laríngeos: resultados de un estudio fase II.
  • OBJECTIVE: To evaluate the results of an induction chemotherapy protocol with Vinorelbine, UFT and Cisplatin (UFTVP).
  • METHODS: 93 patients with laryngo-pharyngeal squamous cell carcinoma in stage III or IV were prospectively entered into a protocol to receive four cycles of UFTVP.
  • Responders followed definitive radiation therapy.
  • RESULTS: Following chemotherapy nodal response (complete in 28% and partial in 33%) was less than that the primary site (complete in 60% and partial in 30%), p = 0.002.
  • With a median follow-up of 62 months, the Kaplan-Meier 5-year survival was 45%.
  • Lymph node metastases and pharyngeal localization were found to be significant negative factors with regards to survival.
  • CONCLUSIONS: UFTVP is an active regime of chemotherapy in advanced squamous cell carcinoma of the pharynx and larynx.
  • Results differ according to the localization, having significantly better rates of survival and organ preservation in the laryngeal cancers that in those of the pharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngectomy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Prospective Studies. Remission Induction. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15164709.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; 1-UFT protocol
  •  go-up   go-down


2. Yi W, Liu XM, Xia YF, Liu Q, Li JT: [Influence of level-Ib lymphadenopathy on the prognosis of nasopharyngeal carcinoma]. Chin J Cancer; 2010 Jan;29(1):87-93
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: The level-Ib lymph node metastasis is rare in nasopharyngeal carcinoma (NPC).
  • METHODS: From January 1990 and December 1999, 933 newly diagnosed patients with NPC treated at Sun Yat-sen University Cancer Center were randomly selected, examined with computed tomography (CT) imagining for evidence of level-Ib lymphadenopathy before treatment.
  • All patients received radical radiotherapy with or without chemotherapy.
  • The relationship between level-Ib lymphadenopathy and post-treatment outcomes including overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were analyzed using Kaplan-Meier methods.
  • In the subgroup with carotid sheath involvement, with multivariate analysis accounting for all previously known prognostic factors, level-Ib lymphadenopathy was still associated with a risk of decreased OS (RR, 2.124; P<0.001), DMFS (RR, 2.168; P<0.001), and LRFS (RR, 1.989; P=0.001).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Cobalt Radioisotopes / therapeutic use. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Particle Accelerators. Pharynx / pathology. Prognosis. Proportional Hazards Models. Radioisotope Teletherapy. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038317.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


3. Matijevic T, Marjanovic M, Pavelic J: Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand J Immunol; 2009 Jul;70(1):18-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functionally active toll-like receptor 3 on human primary and metastatic cancer cells.
  • To clarify if TLR3, is expressed in certain tumour cell lines and whether it is functional and what is the response of these cell lines to different concentrations of poly I:C treatment, we have screened SW480, SW620, FaDu and Detroit 562 cell lines using real-time PCR, flow cytometry and ELISA.
  • We have shown that all these cell lines express TLR3 on mRNA and protein level but it is only functional in Detroit 562 cell line since only in these cells poly I:C treatment triggered the IL-6 secretion.
  • In addition, poly I:C treatment inhibited cell growth and triggered up-regulation of IL-12p40, IL-8 and Il-1alpha in Detroit 562 cell line.
  • By using annexin-V apoptosis detection kit, we have found that poly I:C triggers apoptosis in Detroit 562 cell line.
  • We have found here that based on the results of TLR3 functionality there is a huge difference between FaDu and Detroit 562 cell lines which are of the same origin (pharynx) but FaDu is primary and Detroit 562 metastatic carcinoma.
  • Our study also shows that Detroit 562 cell line could be a good model for cancer therapy research and development as it is responsive to TLR3 agonists which consequently drives it to apoptosis.
  • [MeSH-major] Neoplasm Metastasis / pathology. Neoplasms / metabolism. Neoplasms / pathology. Toll-Like Receptor 3 / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / physiology. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Interferon Inducers / pharmacology. Poly I-C / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522763.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Inducers; 0 / TLR3 protein, human; 0 / Toll-Like Receptor 3; 24939-03-5 / Poly I-C
  •  go-up   go-down


Advertisement
4. Balm AJ, Schornagel JH, Rasch CR: [The role of simultaneous chemotherapy and radiotherapy in the treatment of locally metastasised tumours of the larynx, pharynx and oral cavity]. Ned Tijdschr Geneeskd; 2005 Jan 8;149(2):61-4
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of simultaneous chemotherapy and radiotherapy in the treatment of locally metastasised tumours of the larynx, pharynx and oral cavity].
  • [Transliterated title] De rol van gelijktijdige chemotherapie en radiotherapie bij de behandeling van lokaal uitgebreide tumoren van larynx, farynx en mondholte.
  • In The Netherlands each year there are 2300 new patients with a squamous-cell carcinoma of the larynx, pharynx and oral cavity, and of these, one-third has a locally regionally advanced tumour.
  • Compared to radiotherapy alone, the combination of radiotherapy and chemotherapy containing cisplatin, when administered simultaneously, produces a higher percentage of patients with loco-regional control and a higher 3-year survival percentage.
  • This improvement in treatment results is accompanied by an increased acute toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Otorhinolaryngologic Neoplasms / drug therapy. Otorhinolaryngologic Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Neoplasm Metastasis. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / radiotherapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688835.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Cheng SH, Tsai SY, Yen KL, Jian JJ, Feng AC, Chan KY, Hong CF, Chu NM, Lin YC, Lin CY, Tan TD, Hsieh CY, Chong V, Huang AT: Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):456-65
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had undergone inadequate radiotherapy at a dose of <60 Gy and/or preradiotherapy chemotherapy before the imaging evaluation were excluded from the study.
  • The 5-year distant metastasis-free survival rate, with and without adjuvant chemotherapy, was 97% and 96%, respectively.
  • Their 5-year recurrence-free survival rate, with and without adjuvant chemotherapy, was 76.8% and 53.2% (p = 0.01), respectively.
  • CONCLUSION: Our findings suggest that the risk of distant metastasis in Stage I-III NPC patients without parapharyngeal space extension or T3 disease is extremely low.
  • Invasion into the parapharyngeal space venous plexus and marrow of the skull base bones is associated with distant metastasis, and involvement of these anatomic sites is considered a potential route for hematogenous disease spread in patients with Stage I-III NPC.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis / prevention & control. Neoplasm Staging. Pharynx. Practice Guidelines as Topic. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667967.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Lee CC, Chu ST, Chou P: Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. Auris Nasus Larynx; 2009 Dec;36(6):688-94
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
  • OBJECTIVES: To evaluate the impact of invasion of the prevertebral or parapharyngeal spaces and large tumor volume on treatment outcomes in patients with nasopharyngeal carcinoma (NPC).
  • All patients received a total dose of 70-75 Gy.
  • RESULTS: After controlling for age, sex, and chemotherapy status, invasion of the prevertebral or parapharyngeal spaces and large primary tumor volume produced a significantly increased hazard ratio for distant metastasis and recurrence.
  • We defined patients with two or more such prognostic factors as high-risk patients, in whom the 3-year metastasis-free survival rate, with and without adjuvant chemotherapy, was 100% and 69.6%, respectively (P=0.02).
  • Their 3-year recurrence-free survival rate, with and without adjuvant chemotherapy, was 93.3% and 70.2% (P=0.09).
  • CONCLUSION: NPC patients with any two or more of the factors, involvement of the prevertebral space, large primary tumor volume, or advanced parapharyngeal space invasion, had more recurrence and poor survival rates and benefited from concurrent chemoradiotherapy followed by adjuvant chemotherapy.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Nasopharynx / pathology. Neoplasm Invasiveness. Neoplasm Staging. Pharynx / pathology. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Tumor Burden / drug effects. Tumor Burden / radiation effects. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410399.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Kyan A, Kato SN: [Renal cell carcinoma metastatic to the base of tongue: a case report]. Hinyokika Kiyo; 2004 Nov;50(11):791-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell carcinoma metastatic to the base of tongue: a case report].
  • He complained of discomfort at his pharynx.
  • An otolaryngeal examination revealed a tumor about 1.3 cm in size at the base of tongue, and the tumor was resected.
  • It was pathologically diagnosed as clear cell carcinoma and as tongue metastasis of RCC.
  • The subsequent appearance of a minute pulmonary metastasis caused the administration of interferon-alpha and interleukin-II.
  • At present, two years after the treatment, neither growth of lung metastasis nor recurrence of tongue tumor are noticed.
  • Tongue metastasis of RCC is rare and its prognosis is poor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary. Tongue Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoplasm Staging. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628540.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  • [Number-of-references] 18
  •  go-up   go-down


8. Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH, Polverini PJ: Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol Cancer Ther; 2008 Jul;7(7):2060-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.
  • Therapeutic radiation is commonly used in the treatment of squamous cell carcinoma of the oral cavity and pharynx.
  • Despite the proven efficacy of this form of anticancer therapy, high-dose radiation treatment is invariably associated with numerous unwanted side effects.
  • This is particularly true for bone, in which radiation treatment often leads to osteoradionecrosis.
  • The aim of this study was to investigate if treatment with arsenic trioxide (As(2)O(3)) could enhance the antitumor effect of radiotherapy whereas minimizing the destructive effects of radiation on bone.
  • As(2)O(3) treatment induced a dose-dependent (1-20 mumol/L) inhibition of endothelial and tumor cell (OSCC-3 and UM-SCC-74A) survival and significantly enhanced radiation-induced endothelial cell and tumor cell death.
  • In contrast, As(2)O(3) treatment (0.5-7.5 mumol/L) induced the proliferation of osteoblasts and also protected osteoblasts against radiation-induced cell death.
  • Furthermore, As(2)O(3) treatment was able to significantly enhance radiation-induced inhibition of endothelial cell tube formation and tumor cell colony formation.
  • To test the effectiveness of As(2)O(3) and radiation treatment in vivo, we used a severe combined immunodeficiency mouse model that has a bone ossicle and tumor growing side by side subcutaneously.
  • Animals treated with As(2)O(3) and radiation showed a significant inhibition of tumor growth, tumor angiogenesis, and tumor metastasis to the lungs as compared with As(2)O(3) treatment or radiation treatment alone.
  • In contrast, As(2)O(3) treatment protected bone ossicles from radiation-induced bone loss.
  • These results suggest a novel strategy to enhance the therapeutic efficacy of radiation treatment while protecting bone from the adverse effects of therapeutic radiation.
  • [MeSH-major] Arsenicals / therapeutic use. Bone and Bones / radiation effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Oxides / therapeutic use
  • [MeSH-minor] Animals. Bone Resorption / pathology. Cell Death / drug effects. Cell Death / radiation effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Endothelial Cells / drug effects. Endothelial Cells / pathology. Endothelial Cells / radiation effects. Humans. Mice. Mice, Inbred BALB C. Mice, SCID. Neoplasm Metastasis. Neovascularization, Pathologic. Osteoblasts / drug effects. Osteoblasts / pathology. Osteoblasts / radiation effects. Radiation, Ionizing. Treatment Outcome. Tumor Stem Cell Assay. Vascular Endothelial Growth Factor A / pharmacology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645016.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 P50 CA097248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 0 / Vascular Endothelial Growth Factor A; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


9. Mevio E, Sbrocca M, Gorini E, Artesi L, Mullace M, Castelli A, Migliorini L: Malignant fibrous histiocytoma of the pharynx. Acta Otorhinolaryngol Belg; 2003;57(1):79-81
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the pharynx.
  • Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life, but is relatively uncommon in the head and neck region.
  • That region has been reported to be the origin of malignant fibrous histiocytoma in 3-10% of cases.
  • Only one case of the tumor occurring in the pharynx has been reported.
  • Histologically it is sometimes hard to distinguish this tumor from some sarcomas and pleomorphic carcinomas.
  • The treatment of choice is a large surgical resection, while radiotherapy and chemotherapy are reserved for recurrences.
  • The authors present a case of oropharyngeal malignant fibrous histiocytoma.
  • For more than 1 year postoperatively, there has been no evidence of the disease or metastasis.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12642957.001).
  • [ISSN] 0001-6497
  • [Journal-full-title] Acta oto-rhino-laryngologica Belgica
  • [ISO-abbreviation] Acta Otorhinolaryngol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


10. Lee CC, Chu ST, Chou P, Lee CC, Chen LF: The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma. Clin Otolaryngol; 2008 Oct;33(5):442-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The purpose of this study was to evaluate the effect of prevetebral space involvement on treatment outcomes in patients with nasopharyngeal carcinoma (NPC) who were treated with radiotherapy/concurrent chemoradiotherpy or concurrent chemoradiotherpy with adjuvant chemotherapy.
  • Thirty-nine patients were excluded because of the presence of distant metastasis at the time of presentation, loss of follow-up and incomplete image information.
  • Pearson's chi-square and Fisher's exact test were also used to evaluate the correlation between failure patterns and treatment modality.
  • Patients with prevertebral space involvement conferred a poor overall survival rate and metastasis-free survival rate compared with those without prevertebral space invasion (P = 0.04 and 0.02 respectively).
  • Multivariate analysis showed that prevertebral space invasion was associated with an increased risk for distant metastasis [hazard ratio (HR) 14, 95% confidence interval (CI) 1.0-17.4; P = 0.03)] and overall survival (HR 7, 95% CI 1.1-135; P = 0.04).
  • In patients with prevertebral space involvement, their metastasis-free survival rate, with and without adjuvant chemotherapy, was 100% and 72.7% (P = 0.047).
  • Nasopharyngeal carcinoma patients with prevertebral space involvement have more recurrence and poorer survival rates and should be the group to benefit from concurrent chemoradiotherapy followed by adjuvant chemotherapy.
  • [MeSH-major] Magnetic Resonance Imaging. Nasopharyngeal Neoplasms / pathology. Neck Muscles / pathology. Pharynx / pathology
  • [MeSH-minor] Adipose Tissue / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cervical Vertebrae / pathology. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Oropharynx / pathology. Prognosis. Retrospective Studies. Skull Base / pathology. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983377.001).
  • [ISSN] 1749-4486
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Corvò R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, Pallestrini E, Merlano M, Vitale V, Rosso R: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer; 2001 Dec 1;92(11):2856-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During 6 years, 136 consecutive patients with previously untreated unfavorable Stage II or Stage III-IV (International Union Against Cancer) SCC of the oral cavity, pharynx, and larynx were enrolled.
  • They were randomly assigned to chemotherapy consisting of 4 cycles of intravenous cisplatin (20 mg/m(2) of body surface area per day for 5 consecutive days) and 5-fluorouracil (200 mg/m(2) per day for 5 consecutive days; weeks 1, 4, 7, and 10) alternated with three 2-week courses of radiotherapy (20 grays [Gy] per course, 2 Gy per day, 5 days per week; ALT, 70 patients) or to partly accelerated radiotherapy with final concomitant boost technique (75 Gy/40 fractions in 6 weeks; partly accelerated radiotherapy [PA-RT], 66 patients).
  • RESULTS: At the median follow-up of 60 months (range, 30-102 months), no statistical differences were observed in overall survival, progression free survival, or locoregional control between the 2 treatments.
  • At multivariate analysis, tumor classification was the only factor that emerged as a significant independent variable affecting overall survival.
  • Therefore, definitive conclusions could not be made.
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Second Primary / etiology. Patient Compliance. Regression Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11753959.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


12. Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, Biörklund A, Jannert M, Westin T, Kaasa S: A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope; 2001 Aug;111(8):1440-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the health-related quality of life (HRQL) of patients with head and neck cancer during and after treatment with radiotherapy, surgery, and chemotherapy.
  • Health-related quality of life was assessed at baseline and at 1, 2, 3, 6, and 12 months after start of treatment by means of the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire and the EORTC head and neck cancer-specific questionnaire.
  • Three hundred fifty-seven patients with cancer in the oral cavity, pharynx, larynx, nose, sinuses, and salivary glands and neck node metastases from unknown primaries filled in the questionnaires at baseline.
  • The general trend was that HRQL deteriorated significantly during treatment, followed by a slow recovery until the 12-month follow-up with few exceptions (senses, dry mouth, and sexuality).
  • The patients with pharyngeal cancer in general reported worse HRQL compared with the other groups and did not reach pretreatment values in several domains.
  • CONCLUSION: Detailed knowledge about the differences between groups and changes over time may aid us in the communication with patients and in the design of intervention studies focusing on improvement of the support and rehabilitation of patients with head and neck cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngeal Neoplasms. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms. Pharyngeal Neoplasms. Prospective Studies

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568582.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Stambuk HE, Karimi S, Lee N, Patel SG: Oral cavity and oropharynx tumors. Radiol Clin North Am; 2007 Jan;45(1):1-20
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers of the oral cavity and pharynx are the most common head and neck cancers in the United States, and squamous cell carcinoma is the most frequent histologic type.
  • As a general rule, surgical resection is the primary treatment for oral cavity squamous cell carcinoma, whereas oropharyngeal squamous cell carcinomas are treated with radiation with or without chemotherapy.
  • A clear understanding of the anatomy and knowledge of clinical behavior and spread patterns of oral cavity and oropharyngeal squamous cell carcinoma are essential for radiologists to make a meaningful contribution to the treatment of these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Imaging. Mouth Neoplasms / diagnosis. Oropharyngeal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Follow-Up Studies. Humans. Lymphatic Metastasis. Mouth / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / radiography. Neoplasm Staging. Oropharynx / pathology. Palatal Neoplasms / diagnosis. Palatal Neoplasms / pathology. Palatal Neoplasms / radiography. Palate, Soft / pathology. Time Factors. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157621.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


14. Issing WJ, Taleban B, Tauber S: [Diagnosis and management of squamous cell carcinoma of the head and neck region with unknown primary. A survey of 167 patients]. Laryngorhinootologie; 2003 Sep;82(9):659-65
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and management of squamous cell carcinoma of the head and neck region with unknown primary. A survey of 167 patients].
  • [Transliterated title] Diagnose und Management von Plattenepithelkarzinomen mit unbekanntem Primärtumor im Kopf-Hals-Bereich.
  • BACKGROUND: Carcinoma of unknown primary is defined as histological diagnosis of metastasis without diagnosis of a primary tumor.
  • The incidence of CUP is stated in the literature between 3 % and 15 % of all patients with an malignant disease.
  • Histological examination of CUP-metastasis of the neck most frequently shows a squamous cell carcinoma.
  • During the 10 year follow-up a primary tumor was found in 36 of the 167 initially diagnosed CUP-patients.
  • In over 90 % of these cases the tumor was localized in the head and neck region.
  • The origin of the tumor was most frequently the tonsilla palatina (n = 7).
  • Primary radiotherapy was the treatment of choice in 28 patients, 8 patients received combined radio-chemotherapy as primary treatment and 7 patients were treated with chemotherapy alone.
  • No treatment was performed in 6 patients.
  • RESULTS: By comparing the treatment methods there was a significant difference of patient survival in regard to the treatment.
  • Patients treated according to treatment-plan II, which includes an additional "diagnostic" tonsillectomy, is significantly higher than that of patients simply undergoing neck dissection and postoperative radiotherapy or primary radiotherapy alone.
  • Treatment of choice in patients with cervical CUP should be a surgical procedure including radical neck dissection and diagnostic bilateral tonsillectomy followed by postoperative radiation of the cervical lymph drainage.
  • DISCUSSION: Bilateral tonsillectomy is especially important and is correlated with a significant improvement of the survival rate in CUP patients.
  • Additional postoperative radiation of the pharynx from the base of the skull to the upper oesophagus should also be considered, in order to treat a possible--small--primary tumor in this region.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Retrospective Studies. Survival Analysis. Time Factors. Tonsillar Neoplasms / surgery. Tonsillectomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14517763.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Wojdas A, Jurkiewicz D, Kenig D, Rapiejko P: [The case of carcinoma adenoides cysticum of the tongue, the trachea and the thyroid gland]. Otolaryngol Pol; 2004;58(6):1151-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a 65-year-old female patient who was for the first time admitted to the clinic in 1997 due to a tuber of the tongue root.
  • The tuber was removed entirely through a central incision, and an apart hypertrophic change has been found on the posterior pharynx wall and in the scar after the tracheostomy carried out during the previous surgery.
  • In all cases carcinoma adenoides cysticum has been found, as well as metastasis into the thyroid gland and the lungs.
  • The patient was qualified for chemotherapy in the Institute of Oncology, which she has been going through periodically every two weeks until now.
  • In February 2003 the patient was re-admitted to the Clinic due to dyspnoea caused by a significant contraction of the trachea which occurred as a result of a focus of carcinoma adenoides cysticum and significantly enlarged lymph glands near the trachea.
  • The presented case describes an exceptionally aggressive and polyfocal regrowth and transformation of a polymorphic adenoma into cancer.
  • [MeSH-minor] Bronchoscopy / methods. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732839.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


16. Laccourreye O, Seccia V, Ménard M, Garcia D, Vacher C, Holsinger FC: Extended lateral pharyngotomy for selected squamous cell carcinomas of the lateral tongue base. Ann Otol Rhinol Laryngol; 2009 Jun;118(6):428-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: In a retrospective review of an inception cohort of 26 patients with an isolated, previously untreated, moderately to well-differentiated invasive squamous cell carcinoma of the lateral tongue base, consecutively managed with an extended lateral pharyngotomy approach at a single tertiary referral care center, the authors review the key surgical points, highlight the potential technical pitfalls, and document the complications and long-term functional and oncological outcomes in terms of survival and local control.
  • METHODS: The adjunctive measures included induction chemotherapy, ipsilateral neck dissection, and postoperative radiotherapy, used in 96.1%, 96.1%, and 38.5% of patients, respectively.
  • The main causes of death were metachronous second primary tumor, intercurrent disease, and distant metastasis, resulting in 84.6%, 64%, and 46.9% 1-, 3-, and 5-year Kaplan-Meier actuarial survival estimates, respectively.
  • As a function of T stage, the 3- and 5-year actuarial local control estimates were 100%, 87.5%, and 90.9% in patients with tumors classified as T1, T2, and T3-T4a, respectively.
  • CONCLUSIONS: Such results suggest that extended lateral pharyngotomy should be integrated among the various conservative treatment options available to patients with selected carcinomas of the lateral tongue base.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neck Dissection / methods. Pharynx / surgery. Tongue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663374.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Benasso M, Vigo V, Bacigalupo A, Ponzanelli A, Marcenaro M, Corvò R, Margarino G: A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck. Radiother Oncol; 2008 Oct;89(1):44-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three courses of cisplatin, 20mg/m(2)/day and 5-fluorouracil, 200mg/m(2)/day, days 1-5 (weeks 1, 4, and 7) alternated to 3 courses of radiotherapy at standard fractionation (weeks 2-3, 5-6, 8-9) up to 60Gy, and gemcitabine, 50mg/m(2) on monday of each week of radiation, were administered to 47 patients with stage IV (42 patients) or relapsed after surgery (5 patients), SCC of the oral cavity, pharynx or larynx.
  • RESULTS: Eighty-five percent of the patients completed the planned treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423671.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Piermattei A, Cilla S, D'Onofrio G, Grimaldi L, Digesù C, Macchia G, Deodato F, Morganti AG: Large discrepancies between planned and actually delivered dose in IMRT of head and neck cancer. A case report. Tumori; 2007 May-Jun;93(3):319-22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The case is reported of a patient with locally recurrent carcinoma of the tongue treated with intensity-modulated radiotherapy (IMRT) (simultaneous integrated boost) plus concurrent chemotherapy, who during the third week of radiotherapy developed grade 3 mucositis.
  • Treatment was interrupted for 10 days until significant resolution of the symptoms.
  • At the time of treatment resumption the patient showed 8% weight loss, and in vivo portal dose verification revealed large discrepancies between the computed and measured doses.
  • A new CT scan showed marked tumor shrinkage and modifications to the critical structures.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Deglutition Disorders / etiology. Dose-Response Relationship, Radiation. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis / radiotherapy. Male. Neoplasm Recurrence, Local / radiotherapy. Organ Size. Pharynx / diagnostic imaging. Pharynx / radiation effects. Radiotherapy Dosage. Tomography, X-Ray Computed. Weight Loss

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679475.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Holsinger FC, Motamed M, Garcia D, Brasnu D, Ménard M, Laccourreye O: Resection of selected invasive squamous cell carcinoma of the pyriform sinus by means of the lateral pharyngotomy approach: the partial lateral pharyngectomy. Head Neck; 2006 Aug;28(8):705-11
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although the lateral pharyngotomy is a well-known surgical procedure, to our knowledge, no published reports have described the results achieved with a lateral pharyngectomy approach in patients with isolated and previously untreated selected invasive squamous cell carcinoma of the lateral wall of the pyriform sinus.
  • METHODS: The medical files and operative charts of 30 patients with an isolated, and previously untreated, squamous cell carcinoma of the pyriform sinus, treated for cure by lateral partial pharyngectomy and primary closure, as well as postoperative radiotherapy (n = 22), and preoperative chemotherapy (n = 8), were retrospectively studied.
  • Overall, 29 patients died, resulting in a 77.7%, 40%, 23.3%, and 15% 1-, 3-, 5- and 10-year Kaplan-Meier actuarial survival estimate, respectively.
  • The use of a platin-based induction chemotherapy (p = .05) regimen was the only variable that was significantly statistically related to local recurrence.
  • CONCLUSION: Partial pharyngectomy by means of the lateral pharyngotomy combined with postoperative radiation therapy is an efficient and function-sparing approach to control selected invasive squamous cell carcinomas of the lateral wall of the pyriform sinus.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Pharyngeal Neoplasms / surgery. Pharyngectomy. Pharynx / surgery
  • [MeSH-minor] Aged. Cause of Death. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786602.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement